Vaccine developer Adimmune sets up first overseas manufacturing site in Indonesia


Adimmune Corp. announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java JIIPE, Indonesia. The JIIPE facility would be larger than the one in Taiwan, aiming at technology platforms for biologics.

In addition to vaccines and biologics developed in house, the new site sets to be a hub in Southeast Asia for CDMO (contract development and manufacturing) of Adimmune, serving Muslim markets. According to Adimmune, production lines dedicated to COVID-19 vaccines would be created given that SARS-CoV-2 may become influenza-like virus. With close proximity to ASEAN nations, the new site also provides capacity for taking on OEM orders from multinational pharmaceutical companies that have products to supply the region.  

Adimmune’s operating at JIIPE marked a new chapter for the company, said Chi-Hsien Chan, Chairman and CEO of Adimmune. This means Adimmune will be working collectively with Indonesian partners to develop SEA markets and beyond for many years to come. The East Java Industrial Park JIIPE has been granted a status as “Special Economic Zone” which is now run by BKMS company. 

Indonesia is the fourth largest country by population and home to Muslims, where Adimmune’s flu vaccine has been Halal-certificated in favour of its business development.

Adimmune is the only vaccine supplier in Asia with cGMP certification from the US, EU, China, Korea and Taiwan. Neary a half of Adimmune’s revenue in 2020 was generated outside of Taiwan, with flu vaccines exported to China, Thailand and Turkey. Approval process of flu vaccines by Adimmune is underway in Middle East and Europe.